Jesper Valbjørn

Title: Jesper Valbjørn: Innovator in Antibody-Drug Conjugates

Introduction

Jesper Valbjørn is a notable inventor based in Veksø, Denmark. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of antibody-drug conjugates (ADCs). His innovative work focuses on improving the formulation and efficacy of these therapeutic agents.

Latest Patents

Jesper Valbjørn holds a patent for "Lyophilized anti-tissue factor antibody-drug conjugates." This patent discloses surfactant-free lyophilized formulations of ADCs, specifically targeting anti-tissue factor ADCs. The formulations are designed to be particularly suitable for an anti-TF ADC based on an auristatin derivative or other similarly hydrophobic drugs. The excipients used in these formulations typically include histidine, sucrose, trehalose, mannitol, and glycine.

Career Highlights

Jesper Valbjørn is currently associated with Genmab A/S, a leading biotechnology company specializing in the development of innovative antibody therapies. His work at Genmab has positioned him as a key player in the advancement of ADC technology.

Collaborations

Jesper collaborates with talented professionals in his field, including Xiaona Jing and Kelly Ann Roby. These collaborations enhance the research and development efforts at Genmab, contributing to the company's success in biopharmaceutical innovation.

Conclusion

Jesper Valbjørn's contributions to the field of antibody-drug conjugates exemplify the importance of innovation in biopharmaceuticals. His patent and work at Genmab A/S highlight his role as a significant inventor in this rapidly evolving industry.